Background {#Sec1}
==========

Worldwide, pancreatic cancer (PaC) is the seventh leading cause of cancer-related mortality \[[@CR1]\]. Resection remains the cornerstone of curative treatment for medically fit patients with resectable locoregional PaC \[[@CR2]\]. However, only a small proportion of patients with PaC undergo resection. In the United States (US) and Europe during 2012--2014, resection rates ranged from 13% (Estonia) to 21% (Slovenia) for all-stage PaC and from 35% (Norway) to 69% (Denmark) for stage I--II PaC \[[@CR3]\]. The 3-year overall survival remains poor even for patients with stages I--II PaC who underwent resection (\< 60 years, 23--39%; 60--69 years, 16--31%; and ≥ 70 years, 17--30%) \[[@CR4]\]. Chemotherapy has been routinely recommended for resected PaC \[[@CR5]--[@CR7]\]; however, it remains challenging to get many patients to adjuvant therapy after pancreatectomy \[[@CR8]\].

Various prognostic factors for PaC including clinical/pathological (e.g., tumor stage, size, differentiation, lymph node status, resection margin, and peri-neural and blood vessel invasion \[[@CR9]--[@CR15]\]), genetic (e.g., *KRAS*, *TP53*, *SMAD4*, and some DNA damage repair genes (e.g., *BRCA1/2* and *MLH1*) \[[@CR16]--[@CR18]\]), and immunological variables (e.g., CD3, CD8, CD68, PD-L1, and HHLA2 \[[@CR19]--[@CR21]\]) have been reported. Further large international comparative studies on survival-associated factors at the *population* level could help to identify differences across countries.

Patients with resected PaC who undergo chemotherapy are a selected group of all PaC patients and have distinct characteristics \[[@CR8]\]. Even within this patient group, survival is heterogeneous. A prognostic model for this specific patient population is important and desirable and could facilitate clinical counseling by informing both patients and doctors of predicted individualized patient survival, guide plans on follow-up and surveillance, aid to survival stratification in international studies, and offer the baseline survival estimates for further molecular or genetic investigations. Furthermore, for resected patients considering subsequent chemotherapy, the predicted results could potentially encourage a proportion of patients with specific characteristics to further receive the standard postsurgical care. Stage is the major prognostic factor for PaC. Notably, survival of patients with disease of the same TNM stage might vary greatly \[[@CR14]\]. Other prognostic factors such as patient age and tumor differentiation could improve individualized survival-prediction. A model incorporating all these factors can be intuitively illustrated using a nomogram \[[@CR22]\]. Apart from two institutional nomograms predicting postsurgical survival in overall patients \[[@CR23], [@CR24]\], *population-based* survival-predicting models specifically for resected PaC patients receiving chemotherapy with international validations and robustness have not been found.

To our knowledge, we herein report the first large international population-based investigation into factors associated with survival in patients with resected TNM stage I--II PaC receiving chemotherapy. We further construct a population-based survival-predicting model with international validations.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Population-based data of resected PaC patients were obtained from the national cancer registries of Belgium, the Netherlands, Slovenia, and Norway, and the US Surveillance, Epidemiology, and End Results (SEER)-18 \[[@CR25]\] database. Data quality was previously described \[[@CR3]\]. Institution-based data were not included due to the highly selected patients. An extensive attempt was made to contact population-based cancer registries, and the contacted registries together with reasons for exclusion are shown in Additional file [1](#MOESM1){ref-type="media"}: Table S1. The participating European national registries, located in Western, Southern, and Northern Europe were those able to provide quality data according to a standardized uniformed data-request form, which ensured the robustness of the results. All variables were uniformly (re)coded across registries. While there were other national population-based registries, they were not always able to provide eligible treatment, TNM staging, or survival data. All patient-level data were anonymous. This real-world observational study was approved by the Ethics Committee of Medical Faculty Heidelberg.

Patients with diagnosis based on death certificate only (DCO)/autopsy or with unknown/obscure follow-up time or vital status were excluded (Additional file [1](#MOESM1){ref-type="media"}: Table S2). Only patients with microscopically confirmed diagnoses of primary invasive TNM stage I--II adenocarcinomas of the exocrine pancreas who underwent surgical resection in 2003 until 2014 were selected. The time period was selected based on data availability and the fact that the fifth and prior editions of TNM staging were incompatible with the sixth/seventh versions used during 2003--2017 \[[@CR7]\]. Since chemotherapy is standard for patients with resected PaC \[[@CR5]--[@CR7]\], we only included those receiving chemotherapy. Individuals with benign/premalignant tumors, non-PaC neoplasms involving the pancreas, neuroendocrine tumors/carcinoids, cystic/mucinous/serous tumors, acinar cell tumors, stromal tumors, sarcomas, germ-cell neoplasms, lymphomas, or peri-ampullar tumors were also excluded (Additional file [1](#MOESM1){ref-type="media"}: Table S3). To minimize the effect of the potential heterogeneity in surgery quality and perioperative care, we excluded cases surviving \< 3 months. Patients with stage III or IV PaC were also excluded since resection is not routinely recommended for these patients \[[@CR5]--[@CR7]\].

Information on demographic (sex and age), clinical (year of diagnosis/surgery and treatment), and pathologic characteristics (topology, morphology, and TNM stage) was retrieved from all participating countries. Data on resection margin (the Netherlands and Slovenia), hospital type (Belgium and the Netherlands), Eastern Cooperative Oncology Group (ECOG) performance status score (Belgium), comorbidities (Eindhoven, the Netherlands), resection type (the US and the Netherlands), tumor size (the US), and positive and harvested lymph node numbers (the US and the Netherlands) were only available in certain registries.

Resection was defined as surgical removal of primary tumor, regardless of being curative or palliative and extents of excision and lymphadenectomy. Tumor topography and morphology were based on the International Classification of Diseases for Oncology (third edition). Stage was defined following the TNM staging system (sixth/seventh edition) and was a combination of pathologic and clinical stages with priority given to pathologic staging. Lymph node ratio was calculated by dividing the number of positive lymph nodes by the number of harvested lymph nodes. Vital status was based on valid national mortality registrations and official population registers.

Statistical analyses {#Sec4}
--------------------

*Data in each country were analyzed separately without pooling*, considering the potential heterogeneity across countries and to avoid the impact of any single large cohort. Descriptive results were reported as the smallest to the largest proportions for categorical variables or medians/means for continuous variables across countries. The cancer incidence rates by sex in each country were retrieved from the Cancer Incidence in Five Continents Volume XI (CI5 XI) by the International Agency for Research on Cancer (IARC), World Health Organization (WHO) (<http://ci5.iarc.fr/CI5-XI/Default.aspx>), which reports the incidence of cancers diagnosed from 2008 to 2012, standardized to the World (WHO 2000--2025) Standard Population.

The Kaplan-Meier method was applied to calculate survival time and rates. Since patients surviving \< 3 months were excluded in this study, the 6- and 9-month survival was calculated as the short-term outcome. The 1-, 2-, 3-, and 5-year survival was computed as the long-term outcome. To assess the independent impact of potential prognostic factors on survival, Cox proportional hazards regression was used. Variables including year of diagnosis, age, sex, tumor location, T and N stages, and differentiation were included as covariates in the main multivariable models. For complete-case analysis, patients with missing data were excluded in multivariable analyses. In the US, results for the white patients were computed for comparison with the total patients, for whom main analyses were performed. In registries with available information, resection margin, hospital type, tumor size, positive and harvested lymph node numbers, lymph node ratio, T and N stages according to the eighth edition following Kamarajah et al. \[[@CR26]\], ECOG score, resection type, and comorbidities were incorporated one by one into the main models to examine the survival association for each of them. The proportional hazards assumption was verified for all variables by plotting the logarithm of the negative logarithm of the survival function against the logarithm of survival time \[[@CR27]\].

Data were centrally analyzed in the German Cancer Research Center. Results were considered statistically significant at two-sided *P* \< 0.05. Analyses were conducted using the SAS software (version 9.4, SAS Institute Inc.).

Nomogram construction and validation {#Sec5}
------------------------------------

The SEER-18 dataset, the largest of the included datasets, was used as the training set for nomogram construction (models based on the other cohorts did not reveal markedly better performance). Age, sex, tumor location, T and N stages, and differentiation were entered as potentially relevant prognostic factors into the initial full multivariable Cox proportional hazards regression model, and the final model was selected through a backward step-down process using the likelihood ratio test with the Akaike information criterion as a stopping rule \[[@CR28]\]. To permit nonlinear associations, continuous variables were modeled using restricted cubic splines where appropriate \[[@CR28]\]. Points assigned to each variable included in the nomogram to predict the median survival time and 1-, 2-, 3-, and 5-year survival probability were proportional to the effect size of that variable in the final multivariable model. To facilitate clinical use, a corresponding online prognostic tool was created with Evidencio (<https://www.evidencio.com/>).

The nomogram was subjected to 1000 bootstrap resamples for internal validation of the training US cohort and was externally validated using the European datasets to assess the international generalizability of the model. The model performance and discrimination ability for predicting survival was numerically evaluated by computing Harrell's concordance index (C-index) \[[@CR28]\]. Comparison of C-indexes of different models followed Hanley et al. \[[@CR29]\]. Calibration of the nomogram for 1-, 2-, 3-, and 5-year survival was done by comparing the predicted with the observed survival. Bootstrapping was used for bias correction \[[@CR28]\].

In sensitivity analyses for the training US cohort, C-indexes were re-calculated after replacing continuous age with age group, N stage with positive lymph node number or lymph node ratio, and sixth/seventh edition of cancer stages with the eighth version, after adding harvested lymph node number and/or tumor size, after limiting patients to those diagnosed after 2009 or white patients, and after stratifying patients by tumor location. The *survival* and *rms* packages in R 3.4.1 (<http://www.r-project.org>) were used.

Results {#Sec6}
=======

Patient characteristics {#Sec7}
-----------------------

In total, 168,949 PaC patients were registered in the population-based registries in 2003/2004--2013/2014 with follow-up until 2015--2016. After excluding patients diagnosed based on DCO/autopsy (*n* = 4403), unresected (*n* = 137,605), receiving no/unknown chemotherapy (*n* = 11,465), with microscopically unconfirmed tumors or with tumors of ineligible pathology (*n* = 1418), with stage 0/III/IV/unknown tumors (*n* = 1856), and with survival\< 3 months or unknown (*n* = 365), 11,837 patients were eligible for analysis (Additional file [1](#MOESM1){ref-type="media"}: Table S2). The detailed counts and frequencies for discrete variables and medians and interquartile ranges for continuous variables are shown in Table [1](#Tab1){ref-type="table"}. Age-standardized PaC incidence was higher for males than for females. Among the participating countries, incidence for males was lowest in Belgium and the Netherlands (7.4 per 100,000) and highest in Slovenia (9.3 per 100,000); for females, incidence was lowest in Belgium (5.6 per 100,000) and highest in the US, Slovenia, and Norway (6.5 per 100,000).Table 1Demographic and clinical characteristics of resected pancreatic cancer patients^1^VariableCategoryThe USBelgiumThe NetherlandsSloveniaNorwayIncidence (per 100,000)^2^Male8.67.47.49.37.8Female6.55.66.16.56.5Years of diagnosis2004--20152004--20132003--20142003--20132003--2014*n*95191105982118113Diagnosis in 2010 or laterYes5635 (59)579 (52)747 (76)67 (57)79 (70)SexFemale4671 (49)522 (47)483 (49)50 (42)58 (51)Age (years)Median (interquartile range)65 (58--72)65 (58--71)64 (57--69)61 (54--68)63 (59--70)Mean ± standard deviation65 ± 1064 ± 1062 ± 961 ± 964 ± 8\< 50706 (7)90 (8)92 (9)11 (9)4 (4)50--592101 (22)264 (24)235 (24)38 (32)29 (26)60--693464 (36)406 (37)417 (42)46 (39)50 (44)≥ 703248 (34)345 (31)238 (24)23 (19)30 (27)Tumor location^3^Pancreas head7314 (83)658 (82)820 (90)97 (92)91 (88)Pancreas body622 (7)58 (7)31 (3)5 (5)4 (4)Pancreas tail845 (10)86 (11)63 (7)3 (3)8 (8)Other738 (8)303 (27)68 (7)13 (11)10 (9)T stage^4^T1494 (5)56 (5)72 (7)0 (0)8 (8)T21192 (13)185 (17)182 (19)8 (7)28 (26)T37815 (82)860 (78)727 (74)108 (93)70 (66)N stage^5^N16339 (67)805 (73)703 (72)97 (84)60 (55)Differentiation^6^Well858 (10)149 (15)91 (11)12 (11)3 (3)Intermediate4540 (52)511 (52)423 (51)44 (40)64 (63)Poor/undifferentiated3266 (38)326 (33)319 (38)55 (50)35 (34)^1^Categorical data are shown as count (percentage \[%\]). For brevity, results for the counterparts in dichotomous variables are omitted. Records are complete otherwise specified below^2^The cancer incidence rates by sex in each country were retrieved from the Cancer Incidence in Five Continents Volume XI (CI5 XI) by the International Agency for Research on Cancer (IARC), World Health Organization (WHO) which reports the incidence of cancers diagnosed from 2008 to 2012, standardized to the World (WHO 2000--2025) Standard Population^3^The percentages of pancreas head, body, tail, and overlapping cancers are the proportions compared to the total tumor cases of the four locations; "other" includes overlapping lesion, pancreas duct, and not otherwise specified location, and its proportion is relative to the whole cases^4^Missing T stage: the US: 18 (\< 1%); Belgium: 4 (\< 1%); the Netherlands: 1 (\< 1%); Slovenia: 2 (2%); Norway: 7 (6%)^5^Missing N stage: the US: 0 (0%); Belgium: 7 (1%); the Netherlands: 0 (0%); Slovenia: 2 (2%); Norway: 3 (3%)^6^Missing differentiation: the US: 855 (9%); Belgium: 119 (11%); the Netherlands: 149 (15%); Slovenia: 7 (6%); Norway: 11 (10%)

Of the analyzed patients, 52--76% were diagnosed in 2010 or later. The proportion of women ranged from 42% (Slovenia) to 51% (Norway) across countries. While the proportion of women was almost identical to that of men in the US, the Netherlands, and Norway, there was a smaller proportion of women in Slovenia (42%). The median age ranged from 61 (Slovenia) to 65 years (the US and Belgium) across countries. Most patients were ≥ 60 years (58% (Slovenia) to 71% (Norway)). The proportion of patients aged ≥ 70 years was greatest in the US (34%) and smallest in Slovenia (19%). Only 4% (Norway) to 9% (the Netherlands and Slovenia) of patients were \< 50 years old. Tumors were most commonly located at pancreas head (82% (Belgium) to 92% (Slovenia)). Only 3% (the Netherlands) to 7% of cancers (the US and Belgium) were located at pancreas body and 3% (Slovenia) to 11% (Belgium) at pancreas tail. Only a minority of patients had T1 (0% (Slovenia) to 8% (Norway)) or T2 cancers (7% (Slovenia) to 26% (Norway)). N1 tumors comprised 55% (Norway) to 84% of all cancers (Slovenia). Most patients had either moderately differentiated (40% (Slovenia) to 63% (Norway)) or poorly differentiated/undifferentiated tumors (33% (Belgium) to 50% (Slovenia)). Only 3% (Norway) to 15% of cancers (Belgium) were well-differentiated.

Survival outcomes {#Sec8}
-----------------

The median survival time ranged from 18 (Slovenia) to 23 months (the US) across countries (Fig. [1](#Fig1){ref-type="fig"}). The short- and long-term survival outcomes are shown in Table [2](#Tab2){ref-type="table"}. The 6-month survival rate ranged from 94% (the US) to 97% (the Netherlands), and the 9-month survival rate varied from 79% (Slovenia) to 90% (Norway). Regarding longer term outcomes, the 1-year survival rate ranged from 69% (Slovenia) to 79% (the Netherlands), and the 3-year survival rate ranged from 21% (Slovenia) to 31% (the US). The 5-year survival rate was lowest in Slovenia (10%), which was about half of that in the US (19%), the Netherlands (20%), or Norway (21%).Fig. 1Kaplan-Meier overall survival curves for patients with resected stage I--II pancreatic cancer receiving chemotherapy in each country. The 95% confidence limits curves and the 95% Hall-Wellner bands are additionally shown. Median survival time (interquartile range) in months and 3-year survival rates (95% confidence interval) are calculated and provided. IQR, interquartile range; CI, confidence intervalTable 2Short- and long-term survival for resected pancreatic cancer patients receiving chemotherapy estimated by the Kaplan-Meier methodSurvivalThe USBelgiumThe NetherlandsSloveniaNorwayOS (95% CI)^1^OS (95% CI)OS (95% CI)OS (95% CI)OS (95% CI)Short-term survival 6-month94 (94--95)95 (94--96)97 (96--98)95 (89--98)96 (91--99) 9-month87 (86--87)86 (84--88)89 (87--91)79 (70--85)90 (83--94)Long-term survival 1-year77 (76--78)77 (74--79)79 (77--82)69 (60--77)77 (67--83) 2-year47 (46--48)46 (43--49)44 (40--47)39 (30--47)46 (36--55) 3-year31 (30--32)29 (26--32)29 (25--32)21 (14--29)27 (18--36) 5-year19 (18--20)17 (14--20)20 (16--23)10 (5--17)21 (12--31)^1^Results were calculated using the Kaplan-Meier method and are shown as survival proportions (95% confidence intervals) \[%\]*OS* overall survival, *CI* confidence interval

Survival-associated factors {#Sec9}
---------------------------

Results from multivariable Cox regression are shown in Table [3](#Tab3){ref-type="table"}, and only significant results are described. Increasing age was associated with worse survival in the US (HR per year = 1.01), Belgium (HR = 1.02), and Norway (HR = 1.04). Survival was significantly worse in men only in the US (HR = 1.10) and in pancreas body compared to head tumors in Norway (HR = 2.67). Compared to T3 cancers, T1 cancers were associated with higher survival in all investigated countries (HR = 0.17--0.70), while T2 cancers were associated with better survival only in the US (HR = 0.86). Negative nodal status was associated with significantly higher survival in the US (HR = 0.65), Belgium (HR = 0.78), and the Netherlands (HR = 0.51). Better differentiation was significantly associated with higher survival in all countries except Slovenia and Norway, and the HRs for well- and intermediately versus poorly/undifferentiated tumors were 0.48--0.68 and 0.61--0.81, respectively. Association patterns and strengths were similar between white and overall US patients.Table 3Association of demographic and clinical variables with overall survival for resected pancreatic cancer patients estimated by adjusted multivariable Cox proportional hazards regressionVariableCategoryThe USThe US (white)BelgiumThe NetherlandsSloveniaNorwayUsed no.8657717097983310996HR (95% CI)^1^HR (95% CI)HR (95% CI)HR (95% CI)HR (95% CI)HR (95% CI)Year of diagnosisPer year; continuous*0.97* (0.96--0.98)*0.97* (0.96--0.98)0.98 (0.95--1.01)0.99 (0.95--1.03)0.96 (0.89--1.03)*0.80* (0.69--0.93)AgePer year; continuous*1.01* (1.01--1.01)*1.01* (1.01--1.01)*1.02* (1.01--1.02)1.00 (0.99--1.01)1.01 (0.99--1.04)*1.04* (1.00--1.08)SexFemale1.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)Male*1.10* (1.05--1.16)*1.12* (1.06--1.18)0.93 (0.80--1.07)1.08 (0.91--1.29)1.49 (0.96--2.32)1.14 (0.67--1.95)Tumor locationPancreas head1.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)Pancreas body1.03 (0.92--1.15)1.04 (0.92--1.17)1.34 (0.99--1.82)1.19 (0.69--2.04)1.33 (0.47--3.81)0.40 (0.05--2.98)Pancreas tail1.02 (0.93--1.12)1.03 (0.93--1.14)1.00 (0.76--1.30)0.85 (0.57--1.26)0.39 (0.09--1.66)*2.67* (1.09--6.53)Other^2^1.02 (0.93--1.13)1.03 (0.93--1.15)0.95 (0.80--1.12)0.92 (0.65--1.38)0.83 (0.37--1.84)0.89 (0.30--2.65)T stageT1*0.66* (0.57--0.75)*0.70* (0.61--0.81)*0.68* (0.47--0.97)*0.48* (0.33--0.71)--*0.17* (0.04--0.72)T2*0.86* (0.79--0.93)*0.88* (0.81--0.97)0.89 (0.74--1.08)1.02 (0.82--1.26)0.70 (0.29--1.67)0.89 (0.49--1.61)T31.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)N stageN0*0.65* (0.61--0.69)*0.65* (0.61--0.69)*0.78* (0.66--0.92)*0.51 (0.41--0.64)*0.77 (0.40--1.51)0.71 (0.39--1.29)N11.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)DifferentiationWell*0.60* (0.55--0.66)*0.59* (0.53--0.65)*0.68* (0.55--0.85)*0.48* (0.35--0.67)0.57 (0.27--1.22)0.31 (0.04--2.58)Intermediate*0.77* (0.73--0.81)*0.78* (0.73--0.82)*0.81* (0.69--0.94)*0.61* (0.50--0.73)0.82 (0.51--1.32)0.93 (0.54--1.61)Poor/undifferentiated1.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)1.00 (reference)^1^HRs were calculated by Cox proportional hazard regression with adjustment for year of diagnosis, age, sex, tumor location, T, N, and M stages, histology, and differentiation. In stratified analyses, the stratification factor was omitted from the model. Statistically significant HRs are shown in italics^2^Other: pancreas duct, overlapping lesion, and not otherwise specified location*HR* hazard ratio, *CI* confidence interval, −, not available

Associations with further variables were explored in countries with available relevant information (Table [4](#Tab4){ref-type="table"}). In the Netherlands, positive resection margin was associated with worse survival in (HR = 1.36), and resection in academic hospital was associated with better survival (HR = 0.79). In the US, larger tumor size was associated with inferior survival, and replacing T stage according to the sixth/seventh edition with the eighth edition revealed similar association patterns and strengths. In the US and the Netherlands, while increasing metastatic node number (HR per positive lymph node = 1.05 and 1.07) and lymph node ratio (HR = 2.60 and 3.15) were associated with inferior survival, more harvested nodes suggested better survival (both HR per harvested node = 0.99). Following the eighth version of TNM staging, N1 (HR = 1.42 and 1.68) and N2 stages (HR = 1.84 and 2.43) were associated with worse survival compared to N0 stage in the US and the Netherlands. In Eindhoven, the Netherlands, more comorbidities were associated with inferior survival (e.g., HR~≥ 2\ vs.\ 0\ comorbidities~ = 1.86).Table 4Association of survival with potential prognostic factors available in at least one registry for resected pancreatic cancer estimated by adjusted Cox proportional hazard regressionVariableThe USBelgiumThe NetherlandsSlovenianHR (95% CI)nHR (95% CI)nHR (95% CI)*n*HR (95% CI)Resection margin Negative--------6371.00 (reference)511.00 (reference) Positive--------291*1.36* (1.12--1.65)341.54 (0.82--2.88)Hospital type Non-academic----4971.00 (reference)5101.00 (reference)---- Academic----6080.89 (0.77--1.03)472*0.79* (0.66--0.94)----Tumor size ≤ 2 cm14901.00 (reference)------------ 2--3 cm3146*1.23* (1.12--1.35)------------ 3--4 cm2487*1.38* (1.25--1.52)------------ 4--5 cm1229*1.60* (1.44--1.78)------------ \> 5 cm938*1.56* (1.39--1.75)------------T stage (8th version) T11490*0.62* (0.57--0.68)------------ T25633*0.81* (0.76--0.87)------------ T321671.00 (reference)------------Positive LN number (continuous)9426*1.05* (1.04--1.06)----974*1.07* (1.04--1.10)----N stage (8th version) N0 (0 positive LNs)31801.00 (reference)----2801.00 (reference)---- N1 (1--3 positive LNs)3885*1.42* (1.33--1.51)----416*1.68* (1.33--2.13)---- N2 (≥ 4 positive LNs)2244*1.84* (1.72--1.98)----278*2.43* (1.89--3.12)----Harvested LN number (continuous)9484*0.99* (0.99--0.99)----9590.99 (0.98--1.00)----LN ratio (continuous)9138*2.60* (2.26--3.00)----945*3.15* (2.05--4.84)----ECOG score 0----1401.00 (reference)-------- 1----6620.96 (0.76--1.20)-------- ≥ 2----631.04 (0.73--1.47)--------Resection type Pancreatoduodenectomy71081.00 (reference)----8771.00 (reference)---- Distal pancreatectomy11421.02 (0.92--1.14)----881.33 (0.61--2.91)---- Total pancreatectomy11021.07 (0.99--1.15)----100.98 (0.36--2.65)----Comorbidity Cardiovascular disease (yes *v* no)--------30/1191.33 (0.69--2.57)---- Hypertension (yes *v* no)--------39/1101.01 (0.59--1.75)---- Diabetes (yes *v* no)--------33/1161.34 (0.76--2.38)---- Pulmonary disease (yes *v* no)--------14/1351.96 (0.88--4.36)----Number of comorbidities 0--------521.00 (reference)---- 1--------481.48 (0.84--2.62)---- ≥ 2--------49*1.86* (1.00--3.46)----^1^The main Cox proportional hazard regression models adjusted for year of diagnosis, age, sex, tumor location, T, N, and M stages, histology, and differentiation. HRs were calculated after N stage was replaced by metastatic node number (group) or lymph node ratio, or after the other investigated variables were included one by one into the main models. Statistically significant HRs are shown in italicsHR, hazard ratio; CI, confidence interval; LN, lymph node; ECOG, Eastern Cooperative Oncology Group; −, not available

Prognostic nomogram {#Sec10}
-------------------

### Construction {#Sec11}

A nomogram incorporating prognostic factors remaining after backward selection in the US (sex, age, T and N stages, and differentiation) was established (Fig. [2](#Fig2){ref-type="fig"}a). The nomogram illustrated age and differentiation to have the largest contributions to prognosis. T and N stages showed moderate impacts on survival. Each number/category of these variables is assigned a score on the *Points* scale. After summing up the total score and locating it on the *Total Points* scale, a line drawn straight down to the *Median Survival* or *1-/2-/3-/5-Year Survival Probability* scale shows the estimated survival time or probability at each time point. The model function is provided in the Additional file [1](#MOESM1){ref-type="media"}: Supplementary Results. Score assignment for specific categories of the variables and survival for different accumulated scores are shown in Table [5](#Tab5){ref-type="table"}. The layout of an online version of the nomogram is shown in Fig. [3](#Fig3){ref-type="fig"}.Fig. 2Prognostic nomogram for patients with resected stage I--II pancreatic cancer receiving chemotherapy derived from the US cohort (**a**) and an example on how to use the nomogram (**b**). Each number/category of the prognostic variables is assigned a score on the *Points* scale. After summing up the total score and locating it on the *Total Points* scale, a line drawn straight down to the *Median Survival* or *1-/2-/3-/5-Year Survival* scale shows the median survival time and estimated survival probability at each time point. Age is in yearsTable 5Score assignment for specific categories of the variables included in the nomogramPrognostic factorsVariableCategoryScore SexFemale0Male18 Age (years)254230343527401945115045506056518702475338046855990739586100100 T stageT10T253T378 N stageN00N182 DifferentiationWell0Intermediate47Poor/undifferentiated97Median survivalTotal scoreMedian survival (months) 25120 15230 9940 6450 4360 2770 1380 0901-year survivalTotal score1-year survival probability 3450.60 3130.65 2770.70 2360.75 1870.80 1260.85 440.902-year survivalTotal score2-year survival probability 3580.20 3290.25 3020.30 2760.35 2500.40 2240.45 1970.50 1690.55 1380.60 1060.65 700.70 290.753-year survivalTotal score3-year survival probability 3420.10 3050.15 2730.20 2450.25 2180.30 1920.35 1660.40 1390.45 1120.50 840.55 540.60 210.655-year survivalTotal score5-year survival probability 3230.05 2720.10 2350.15 2040.20 1750.25 1480.30 1220.35 960.40 700.45 430.50 150.55Fig. 3Calibration curves for 1-, 2-, 3-, and 5-year overall survival prediction in the primary training (the US) and validation cohorts (Belgium, the Netherlands, Slovenia, and Norway). Nomogram-predicted survival is plotted on the *x* axis and actual survival on the *y* axis. The vertical bars at the top represent the frequency of the predicted probability of survival. A plot along the 45-degree line indicates a perfect calibration model where the predicted probabilities are identical to the actual proportions

### An example of use {#Sec12}

An example of how to use the nomogram is shown in Fig. [2](#Fig2){ref-type="fig"}b. A 72-year-old woman with poorly differentiated, T2N1M0 PaC who underwent resection and chemotherapy would have 28 points for her age, 0 points for her sex, 53 points for T stage, 82 points for N stage, and 97 points for differentiation, totaling 260 points. The total points correspond to the estimation of median survival time of \< 20 months, a 1-year survival probability of 72%, a 2-year survival probability of 38%, a 3-year survival probability of 22%, and a 5-year survival probability of 12%, which are consistent with the results generated by the online tool (Fig. [3](#Fig3){ref-type="fig"}).

### Calibration and validation {#Sec13}

The nomogram was applied to the US and the European countries for internal and external validations, respectively. The calibration plots showed very good agreement between nomogram-predicted and actual survival in the US, Belgium, and the Netherlands (Fig. [4](#Fig4){ref-type="fig"}; plots were not shown in Slovenia or Norway where the case number was too small to generate meaningful calibration). Generally, the calibration was best for 2- and 3-year survival. In the training US cohort, the C-index for the established nomogram was significantly higher than that for the model based on both T and N stages (0.60, 95% CI = 0.59--0.61 vs. 0.56, 95% CI = 0.56--0.57). In the validation cohorts, C-indexes were also significantly higher for the nomogram than for the T and N stage-based model (Table [6](#Tab6){ref-type="table"}).Fig. 4Layout of an online version of the developed nomogram with Evidencio (<https://www.evidencio.com/models/show/1258>)Table 6Concordance indexes for resected pancreatic cancer in training and validation cohorts and in sensitivity analyses for the training US cohortModel modification/subgroupConcordance index95% confidence intervalTraining cohort The US, our nomogram0.600.59--0.61 The US, model based on both T and N stages0.560.56--0.57Validation cohorts Belgium, our nomogram0.580.55--0.60 Belgium, model based on both T and N stages0.540.52--0.56 The Netherlands, our nomogram0.620.59--0.65 The Netherlands, model based on both T and N stages0.560.54--0.59 Slovenia, our nomogram0.580.51--0.65 Slovenia, model based on both T and N stages0.520.47--0.57 Norway, our nomogram0.630.55--0.71 Norway, model based on both T and N stages0.610.54--0.68Sensitivity analyses for the training US cohort Replacement  Age group in place of continuous age0.590.59--0.60  Metastatic lymph node number in place of N stage0.600.59--0.61  Lymph node ratio in place of N stage*0.61*0.61--0.62  The 8th version of T stage in place of the original stage*0.61*0.60--0.61  The 8th version of N stage in place of the original stage0.600.59--0.61  The 8th version of T & N stages in place of the original stages*0.61*0.60--0.62 Addition  Harvested lymph node added0.600.60--0.61  Tumor size added*0.61*0.60--0.61  Harvested lymph node & tumor size added*0.61*0.60--0.62 Subgroup  Diagnosis after 20090.600.59--0.61  White ethnicity0.600.59--0.61  Pancreas head0.600.59--0.61  Pancreas body & tail*0.61*0.59--0.63Concordance indexes in sensitivity analyses greater than that for the overall nomogram in the US are highlighted in italics

### Sensitivity analyses {#Sec14}

Sensitivity analyses were performed for the derivative US cohort (Table [6](#Tab6){ref-type="table"}). Using positive lymph node number or lymph node ratio instead of N stage in the nomogram did not obviously change the C-index (by 0.00 and + 0.01, respectively). Replacing the sixth/seventh version of both T and N stages with the eighth version also had minimal impact on the C-index (by + 0.01). After including examined lymph node number, tumor size, or both, the C-index only changed by 0.0, + 0.01, and + 0.01, respectively. Limiting the sample to patients diagnosed after 2009 or white people did not change the C-index. Within subgroups according to tumor location, C-index was slightly higher than the overall one in body/tail cancer (0.61).

Discussion {#Sec15}
==========

In our large population-based study, we identified various factors independently associated with survival after resection of PaC and for the first time established and internationally validated a population-based nomogram for predicting survival in resected PaC patients receiving chemotherapy, which is robust, accurate, reliable, and practical. However, like previous models \[[@CR23], [@CR24], [@CR30]--[@CR32]\], our model had a modest C-statistic.

There are various reports on the prognostic factors for patients who underwent resection for PaC \[[@CR9]--[@CR15]\]. A systematic review showed that with the exception of postsurgical blood transfusion, tumor characteristics (e.g., size, lymph node status, and differentiation) were the only features significantly associated with survival after pancreatic resection \[[@CR9]\]. Particularly, PaC size \> 2 cm was an independent factor associated with poor post-surgical prognosis \[[@CR10]\], and this category has been incorporated in both the sixth/seventh and the eighth TNM staging systems \[[@CR33], [@CR34]\]. Notably, neural invasion was also determined to be an independent prognostic factor in PaC \[[@CR11]\]. Through multivariable analyses, we demonstrated that older age, more advanced T and N stages, and poorer differentiation were independently associated with lower overall survival in resected PaC across most countries. In registries with available information, resection margin, hospital type, tumor size, metastatic and harvested lymph node numbers, lymph node ratio, and comorbidity number were also associated with prognosis. These findings are mostly consistent with previous literature \[[@CR9]--[@CR15], [@CR35], [@CR36]\] and add insights into the association strengths for resected PaC patients receiving chemotherapy at the population level and into the comparisons between countries. Some patient (e.g., age and comorbidities) and clinical characteristics (e.g., hospital type) were further identified to be prognostically significant. While previous studies have drawn differing conclusions regarding the association between resection type and survival \[[@CR35], [@CR36]\], our population-based investigation of chemotherapy-treated resected PaC patients did not show a significant association. Furthermore, we found mostly no significant associations between tumor location and survival.

Notably, overall, the contribution of T or N stage to postoperative survival was mostly not greater than that of differentiation. Categorization of tumor size and number of metastatic lymph nodes following the eighth TNM staging system \[[@CR33], [@CR34]\] discriminated survival well, supporting the implementation of the new system. Notably, harvested lymph node number was positively associated with survival. The relevance of harvested lymph node number for survival has remained controversial in PaC \[[@CR37], [@CR38]\]. Possible reasons supporting the positive association include that more metastasized lymph nodes may be removed with more extensive sampling, which also results in more precise staging, guiding appropriate post-surgical treatment.

Estimating mortality risk might impact treatment planning and provide information helpful for patient stratification in study design, contributing to better equivalence between study arms \[[@CR39]\]. Post-surgical survival for patients with PaC is remarkably heterogeneous, even with the same TNM stage \[[@CR14], [@CR40], [@CR41]\]. To our knowledge, the nomogram we developed is the first one derived from a large population-based database with long-term follow-up for predicting overall survival in patients with resected stage I--II PaC receiving chemotherapy, with international validations in multiple European national datasets. There is a previous institutional nomogram \[[@CR23]\] developed by Memorial Sloan-Kettering Cancer Center (MSKCC) in 2004 for predicting post-surgical survival in Western PaC patients not accounting for chemotherapy, with three external institutional validation attempts \[[@CR30]--[@CR32]\]. Based on institutional patient cohorts diagnosed many years ago \[[@CR23], [@CR30]--[@CR32]\], the score assignment of several variables might not be optimal currently using the MSKCC nomogram, which might also be limited in generalizability. The MSKCC nomogram did not employ a backward selection process and incorporated some detailed surgical (e.g., portal vein resection and splenectomy) and symptom parameters (back pain and weight loss). Notably, portal vein resection and splenectomy might not be routine procedures during pancreatectomy, and reporting of symptoms might show great interpersonal variations. Our population-based nomogram thus represents a more updated prognostic model compared to the MSKCC nomogram (Additional file [1](#MOESM1){ref-type="media"}: Table S5). The wide geographical distribution of patients and large sample size further enhanced the international representativeness and generalizability of our nomogram.

Resection margin, which reflects the radicality of surgery, has not received a universal standard definition in PaC \[[@CR42], [@CR43]\], and its relevance for survival remains highly controversial \[[@CR44], [@CR45]\]. While we showed a positive association of survival with negative margin in the Netherlands, the strength was not greater than that of the association with T stage, N stage, or differentiation. We did not incorporate this variable in our nomogram for better generalizability. It is encouraged to incorporate margin status into our nomogram when a standard definition comes.

Calibration plots demonstrated very good agreement between nomogram-predicted and actual survival, which assures the repeatability and reliability of our nomogram. Importantly, the model based on the US dataset also fits the multiple European national cohorts, which supports the potential for the generalization and international utilization of our nomogram, *irrespective of the potential health care disparity across countries*. Discrimination of the nomogram, as highlighted by the C-index, was significantly and markedly higher compared to the model based on T and N stages only. In the external validation cohorts, the discriminative potency only slightly changed. Our model performed similarly well across countries, potentially facilitating patient allocation in international studies.

In sensitivity analyses, we examined various alternative models by for instance incorporating positive lymph node number or lymph node ratio as a continuous variable in place of N stage into the nomogram, and the discrimination ability basically remained the same, supporting the robustness of our model.

Notably, the eighth edition of TNM staging system has been implemented since 2018 \[[@CR33], [@CR34]\]. Compared to the sixth/seventh version, in the eighth version new categories of tumor size (≤ 2, 2--4, and \> 4 vs. ≤ 2 and \> 2 cm) and positive node number (0, 1--3, and ≥ 4 vs. 0 and ≥ 1) are incorporated into T and N staging, respectively \[[@CR26], [@CR33], [@CR34]\]. However, after integrating these factors either as continuous or corresponding categorical variables into our nomogram, the performance did not markedly change. After transforming the SEER-18 staging data according to the eighth edition following Kamarajah et al. \[[@CR26]\], the performance also remained very similar. Moreover, it will take considerable follow-up time for the survival associated with the new staging system to be adequately assessed. Therefore, our nomogram will still be applicable without compromised accuracy in the coming years.

Strengths of our study include the international population-based design, the largest number of patients with resected PaC ever investigated, the extensive potential prognostic factors studied, the *uniformly and consistently defined variables* especially TNM stage across countries, and the consistency and quality control in reporting through applying rigorous registry data standards. *Analyses were performed separately in each respective country without pooling*, which avoids the impact of the potential heterogeneity across countries.

Our work may have important clinical impacts and provides to our knowledge the first population-based model which can predict survival for patients with stage I--II PaC who underwent resection and chemotherapy. The model is robust, accurate, well-generalizable, practical, and easy-to-use. Our model may offer personalized patient survival estimates and facilitate clinical counseling for both patients and doctors. Having an idea about the estimated survival of a specific patient could influence plans on follow-up and surveillance (e.g., frequency and examination modality) and thus possibly guide resource allocation. For some proportion of the resected patients considering further treatment, the predicted survival might encourage receipt of further chemotherapy. The international validation assures that our model could be used for survival stratification in international studies.

Patients with resected PaC do not respond equally to chemotherapy, and accordingly, the calibration plots also suggest that individual survival varied greatly despite the relatively consistent comprehensive survival across countries. Our study will help to initially stratify this patient population into subgroups with discrepant survival, and might serve as a platform for developing further endeavors to understand factors associated with chemotherapy responses and survival in resected PaC, including precise, individualized, and personalized genomic and proteomic survivorship investigations.

Like any observational registry-based investigation, our study also has some limitations. Our model predicts survival at the average population level, and when applying this model in specific centers or regions with different care patterns, there could be some inconsistencies between predicted and actual survival. Nevertheless, as revealed by the calibration plots, the real-world survival was still in good accordance with the prediction for a single individual. Residual confounding is a concern. Some significant variables (e.g., tumor size) were only registered in certain databases. Differences in survival pattern across countries might be partly associated with variation in the prescription of chemotherapy and/or the underlying ethnic/racial distribution, even though association results remained similar after limiting the US cohort to white. Notably, there were some differences in patient and tumor characteristics across registries. For instance, in Slovenia, tumors were generally more advanced and poorly differentiated, and the actual survival was the lowest. Nevertheless, these variables were adjusted for in our multivariable analyses.

Population-based registries collected limited information on variables including family and patient health history and individual-level socioeconomic status. In addition, we were unable to determine the molecular or genetic subtype of PaC \[[@CR16]\], which probably plays a role in prognosis and explains the moderate C-index of our nomogram. Accordingly, our nomogram is limited by failure to incorporate these and other recognized prognostic parameters (e.g., neurovascular invasion and type of chemotherapy). Further efforts on collection and incorporation of more relevant variables are encouraged to improve this model.

Notably, all known models predicting PaC survival perform very modestly \[[@CR23], [@CR24], [@CR30]--[@CR32]\]. Our nomogram with selection of only chemotherapy-treated resected PaC patients does not perform better compared to previous models with selection of all patients undergoing resection \[[@CR23], [@CR24], [@CR30]--[@CR32]\], which might limit the added value of the selection for the current nomogram. The lack of detailed information on chemotherapy which has not been routinely collected in most registries is another limitation of this population-based registry-based study. Collection of such information is strongly encouraged in future registration practice. During the study period, the type of chemotherapy was mainly gemcitabine monotherapy, followed by 5-fluorouracil-based therapy. The ESPAC-3 \[[@CR46]\] and RTOG 97-04 randomized trials \[[@CR47]\] demonstrated similar efficacy and effectiveness regarding survival between gemcitabine and 5-fluorouracil in the adjuvant setting. The landscape of systemic treatment (e.g., agent and formula) and treatment sequence for PaC are rapidly changing, which might limit the possible use of this nomogram.

Despite the moderate C-index, the agreement between predicted and actual survival was very good. All variables included in our nomogram are easily available in clinics, compared to the not routinely measured and costly molecular markers. It is herein the first time that the contributions of these risk factors are quantified and integrated into a single model for survival prediction in resected and chemotherapy-treated PaC with international validations.

Conclusions {#Sec16}
===========

This large international population-based investigation revealed independent factors associated and not associated with survival in patients with resected stage I--II PaC receiving chemotherapy, with country-specific association patterns and strengths. We further established and internationally validated a novel, robust, and reliable survival-predicting model, which may provide the basis for more precise individualized survival estimation and which could be useful for clinical counseling. Our nomogram in line with all known models predicting survival in resected PaC performs modestly.

Additional file
===============

 {#Sec17}

Additional file 1:**Table S1.** Selection of contacted national population-based cancer registries in Europe. **Table S2.**General information on participating population-based registries. **Table S3.** Inclusion and exclusion codes according to International Classification of Diseases for Oncology, Third Edition. **Table S4.** Comparison of the Memorial Sloan-Kettering Cancer Center nomogram with the nomogram established in this study for survival in resected pancreatic cancer for Western patient. (DOCX 33 kb)
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